Hanmi announces positive clinical data on Amozaltan
Published: 2009-05-20 06:56:00
Updated: 2009-05-20 06:56:00
Hanmi Pharm announced positive Phase III data on its new medicine, Amozaltan (amlodipine + losartan), an oral antihypertensive agent, at the local congress hosted by the Korean Society of Nephrology and the Korean Society of Hypertension.
The trial showed that Amozaltan is safe, effective, an...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
